Drug
Itepekimab clinical trials
Also written REGN3500 and SAR440340.
- studies test it
- 17
- open now
- 0
- in phase 3
- 7
- first study started
- 2016
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses itepekimab is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 3SanofiNCT06834360Written as Itepekimab (SAR440340)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 3SanofiNCT06834347Written as Itepekimab (SAR440340)
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3SanofiNCT04701983Written as Itepekimab SAR440340
- An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 3SanofiNCT07424144Written as Itepekimab (SAR440340)
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3SanofiNCT04751487Written as Itepekimab SAR440340
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis BronchiectasisCompletedPhase 2SanofiNCT06280391Written as Itepekimab (SAR440340)
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDCompletedPhase 3SanofiNCT06208306Written as Itepekimab (SAR440340)
- Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDCompletedPhase 2SanofiNCT05326412Written as Itepekimab SAR440340
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal PolypsCompletedPhase 2SanofiNCT06691113Written as Itepekimab (SAR440340)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal PolypsWithdrawnPhase 3SanofiNCT07484230Written as Itepekimab (SAR440340)
- Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 2SanofiNCT03546907Written as SAR440340
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma ParticipantsCompletedPhase 2SanofiNCT03387852Written as SAR440340
- Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedPhase 2Regeneron PharmaceuticalsNCT03738423Written as REGN3500
- Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedPhase 2Regeneron PharmaceuticalsNCT03736967Written as REGN3500
- Study of REGN3500 and Dupilumab in Patients With AsthmaCompletedPhase 1Regeneron PharmaceuticalsNCT03112577Written as REGN3500
- Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate AsthmaCompletedPhase 1Regeneron PharmaceuticalsNCT02999711Written as REGN3500
- A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult SubjectsCompletedPhase 1Regeneron PharmaceuticalsNCT02958436Written as REGN3500
Codes
What other systems call itepekimab · ClinicalTrials.gg INT001738
- MeSH (NLM) C000720033itepekimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WV9KZ9PS1AITEPEKIMABConfirmed FDA, NLM
- NCI Thesaurus C174938ItepekimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720033 | itepekimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WV9KZ9PS1A | ITEPEKIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C174938 | Itepekimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.